U.S. markets closed
  • S&P Futures

    4,566.75
    +1.50 (+0.03%)
     
  • Dow Futures

    35,660.00
    +16.00 (+0.04%)
     
  • Nasdaq Futures

    15,542.50
    -2.50 (-0.02%)
     
  • Russell 2000 Futures

    2,292.00
    -1.90 (-0.08%)
     
  • Crude Oil

    84.43
    -0.22 (-0.26%)
     
  • Gold

    1,793.30
    -0.10 (-0.01%)
     
  • Silver

    24.17
    +0.08 (+0.34%)
     
  • EUR/USD

    1.1606
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    1.6190
    -0.0160 (-0.98%)
     
  • Vix

    15.98
    +0.74 (+4.86%)
     
  • GBP/USD

    1.3770
    +0.0006 (+0.05%)
     
  • USD/JPY

    114.1270
    -0.0020 (-0.00%)
     
  • BTC-USD

    60,810.59
    -2,090.85 (-3.32%)
     
  • CMC Crypto 200

    1,473.00
    -32.15 (-2.14%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    28,970.90
    -135.11 (-0.46%)
     

Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless of prior nephrectomy (surgical removal of a kidney) status.

  • Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).

  • The Phase 3 CheckMate-9ER evaluated Cabometyx combined with Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) versus Pfizer Inc's (NYSE: PFE) Sutent (sunitinib).

  • At a median follow-up of 23.5 months, in the patient group with prior nephrectomy, the Cabometyx combo showed a median PFS of 19.4 months versus 8.9 months in the sunitinib arm.

  • Median PFS in patients without nephrectomy was 11.3 months versus 7 months.

  • ORR for prior nephrectomy was 60.8% versus 30.5% and without prior nephrectomy was 41.6% vs. 23.2%

  • Complete response for each patient group was (11.3% versus 6.0%) and (5.0 versus 0%) respectively.

  • The duration of response was (22 months vs. 13.8 months) and (17.2 months and 9.9 months).

  • Price Action: EXEL shares closed 1.69% higher at $20.47 on Wednesday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.